Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview

被引：28

作者：

Mulakayala, Naveen ^{[1
]}

Rao, Pallavi ^{[1
]}

Iqbal, Javed ^{[1
]}

Bandichhor, Rakeshwar ^{[2
]}

Oruganti, Srinivas ^{[1
]}

机构：

[1] Inst Life Sci, COSMIC Discoveries, Hyderabad 500046, Andhra Pradesh, India

[2] Dr Reddys Labs Ltd, Integrated Prod Dev, API R&D, Hyderabad 500072, Andhra Pradesh, India

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2013年 / 60卷

关键词：

Multiple sclerosis; T- and B-lymphocytes; Fingolimod; Laquinimod; Cladribine; Teriflunomide; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ACID RELATED-COMPOUNDS; IMMUNOMODULATORY DRUG FTY720; MONITORED DISEASE-ACTIVITY; SODIUM-SALT GLYCOSYLATION; DOUBLE-BLIND; GLATIRAMER ACETATE; PHASE-II; 2-CHLORO-2'-DEOXYADENOSINE CLADRIBINE; IMMUNOSUPPRESSIVE ACTIVITY;

D O I：

10.1016/j.ejmech.2012.10.055

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Multiple sclerosis (MS) often results in chronic inflammatory and autoimmune disorders, and recent developments in understanding the disease pathogenesis has lead to newer therapeutic options for the treatment of the disease. The development of small molecule drugs with improved efficacy, better tolerability, and oral administration has received a new impetus with the discovery of newer classes of drugs. In this review, we have summarized the hitherto known synthetic strategies of fingolimod, laquinimod, cladribine, and teriflunomide reported in the literature which are the key small molecules and the first oral drug candidates for MS in various stages of clinical development or have been launched in the market. (C) 2012 Elsevier Masson SAS. All rights reserved.

引用

页码：170 / 186

页数：17

共 165 条

[1] Synthesis, solubility, and reaction of long alkyl-chained hypervalent iodine benzyne precursors [J].

Abe, T ;

Yamaji, T ;

Kitamura, T .

BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, 2003, 76 (11) :2175-2178

[2] DESIGN, SYNTHESIS, AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF 2-SUBSTITUTED-2-AMINO-1,3-PROPANEDIOLS - DISCOVERY OF A NOVEL IMMUNOSUPPRESSANT, FTY720 [J].

ADACHI, K ;

KOHARA, T ;

NAKAO, N ;

ARITA, M ;

CHIBA, K ;

MISHINA, T ;

SASAKI, S ;

FUJITA, T .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (08) :853-856

[3] Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis [J].

Andersen, O ;

Lycke, J ;

Tollesson, PO ;

Svenningsson, A ;

Runmarker, B ;

Linde, AS ;

Astrom, M ;

Gjorstrup, P ;

Ekholm, S .

NEUROLOGY, 1996, 47 (04) :895-900

[4]

[Anonymous], 2008, ATLAS MULTIPLE SCLER, P56

[5]

Barai VN, 2002, HELV CHIM ACTA, V85, P1901, DOI 10.1002/1522-2675(200207)85:7<1901::AID-HLCA1901>3.0.CO

[6]

2-C

[7]

Bartlett R.R., 1996, [No title captured], Patent No. [US 5504084, 5504084]

[8]

Bartlett R.R., 1996, Patent, Patent No. [US 5494911, 5494911, US5494911]

[9] GAS-PHASE THERMAL REARRANGEMENTS OF POTENTIAL VINYLIDENE PRECURSORS TO SILYLBENZOFURANS AND SILYLBENZOPYRANS [J].

BARTON, TJ ;

GROH, BL .

JOURNAL OF ORGANIC CHEMISTRY, 1985, 50 (02) :158-166

[10] The treatment of chronic progressive multiple sclerosis with cladribine [J].

Beutler, E ;

Sipe, JC ;

Romine, JS ;

Koziol, JA ;

McMillan, R ;

Zyroff, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (04) :1716-1720

← 1 2 3 4 5 6 7 8 9 10 →